USPTO serial 79243223
LIPTIDE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 28, 2020
- Examiner
- COLLOPY, DIANE PATRICIA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with LIPTIDE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Thomas W. Cole
Thomas W. Cole RobertsMlotkowskiSafranCole&CalderonP.C.7918 Jones Branch Drive Suite 500McLean, VA 22102UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; chemicals for pharmaceutical use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations being nanoparticles for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing siRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing RNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing shRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing mRNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; pharmaceuticals and pharmaceutical preparations containing DNA for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceuticals and pharmaceutical preparations containing lipids, liposomes or peptides for treatments in the form of gene therapy used in the treatment of cancer; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations in the form of nanoparticles; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; preparations for detecting genetic predispositions for medical purposes; pharmaceuticals and pharmaceutical preparations for use in gene therapy in the form of nanoparticles used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; pharmaceutical and natural remedies for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biochemical preparation for medical purposes for treatments in the form of gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy used in the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma and other eye diseases, bone diseases, vascular diseases, liver disease, immune system related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 28, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 19, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 26, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 8, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 5, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 28, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 28, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 3, 2020 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 18, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 18, 2020 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 11, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 11, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 7, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 22, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 22, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 22, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 3, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 26, 2019 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 28, 2019 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 28, 2019 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 28, 2019 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 7, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 7, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2019 | ALIE | ASSIGNED TO LIE | — |
| May 29, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 11, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 28, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 7, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 7, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 24, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 23, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 23, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 19, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 18, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |